Compare · MSFT vs PEAR
MSFT vs PEAR
Side-by-side comparison of Microsoft Corporation (MSFT) and Pear Therapeutics Inc. (PEAR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MSFT and PEAR operate in Computer Software: Prepackaged Software (Technology), so they compete in similar markets.
- MSFT is the larger of the two at $2.95T, about 5506.6x PEAR ($536.0M).
- MSFT has hit the wire 29 times in the past 4 weeks while PEAR has been quiet.
- MSFT has more recent analyst coverage (25 ratings vs 6 for PEAR).
- Company
- Microsoft Corporation
- Pear Therapeutics Inc.
- Price
- $397.38-1.42%
- $0.03-36.03%
- Market cap
- $2.95T
- $536.0M
- 1M return
- -3.69%
- -
- 1Y return
- -15.62%
- -
- Industry
- Computer Software: Prepackaged Software
- Computer Software: Prepackaged Software
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1986
- 2021
- News (4w)
- 29
- 0
- Recent ratings
- 25
- 6
Microsoft Corporation
Microsoft Corporation develops, licenses, and supports software, services, devices, and solutions worldwide. Its Productivity and Business Processes segment offers Office, Exchange, SharePoint, Microsoft Teams, Office 365 Security and Compliance, and Skype for Business, as well as related Client Access Licenses (CAL); Skype, Outlook.com, OneDrive, and LinkedIn; and Dynamics 365, a set of cloud-based and on-premises business solutions for organizations and enterprise divisions. Its Intelligent Cloud segment licenses SQL, Windows Servers, Visual Studio, System Center, and related CALs; GitHub that provides a collaboration platform and code hosting service for developers; and Azure, a cloud platform. It also offers support services and Microsoft consulting services to assist customers in developing, deploying, and managing Microsoft server and desktop solutions; and training and certification on Microsoft products. Its More Personal Computing segment provides Windows original equipment manufacturer (OEM) licensing and other non-volume licensing of the Windows operating system; Windows Commercial, such as volume licensing of the Windows operating system, Windows cloud services, and other Windows commercial offerings; patent licensing; Windows Internet of Things; and MSN advertising. It also offers Surface, PC accessories, PCs, tablets, gaming and entertainment consoles, and other devices; Gaming, including Xbox hardware, and Xbox content and services; video games and third-party video game royalties; and Search, including Bing and Microsoft advertising. It sells its products through OEMs, distributors, and resellers; and directly through digital marketplaces, online stores, and retail stores. It has collaborations with Dynatrace, Inc., Morgan Stanley, Micro Focus, WPP plc, ACI Worldwide, Inc., and iCIMS, Inc., as well as a strategic relationship with Avaya Holdings Corp. Microsoft Corporation was founded in 1975 and is headquartered in Redmond, Washington.
Pear Therapeutics Inc.
Pear Therapeutics, Inc. engages in developing and commercializing software-based medicines. The company has a pipeline of products and product candidates across therapeutic areas, including severe psychiatric and neurologic conditions. Its products include PearConnect, a patient service center for prescription digital therapeutics; reSET for the treatment of substance use disorder; reSET-O for the treatment of opioid use disorder; and Somryst for the treatment of chronic insomnia. The company was founded in 2013 and is based in Boston, Massachusetts.
Latest MSFT
- EVP, Chief Marketing Officer Numoto Takeshi sold $1,031,125 worth of shares (2,500 units at $412.45), decreasing direct ownership by 5% to 51,968 units (SEC Form 4)
- Microsoft announces quarterly dividend
- SEC Form 4 filed by Director Rainey John D
- SEC Form 4 filed by Director Johnston Hugh F
- SEC Form 4 filed by Director Pritzker Penny S
- Director Scharf Charles W was granted 149 shares, increasing direct ownership by 0.33% to 45,041 units (SEC Form 4)
- SEC Form 4 filed by Director Mason Mark
- Director List Teri was granted 149 shares (SEC Form 4)
- SEC Form 4 filed by Director Macgregor Catherine
- Director Stanton John W was granted 149 shares, increasing direct ownership by 0.18% to 84,054 units (SEC Form 4)
Latest PEAR
- SEC Form 25-NSE filed by Pear Therapeutics Inc.
- SEC Form SC 13D/A filed by Pear Therapeutics Inc. (Amendment)
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Stocks That Hit 52-Week Lows On Tuesday
- Why Glory Star New Media Group Shares Are Trading Higher By 122%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- Stocks That Hit 52-Week Lows On Monday
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Why Marpai Shares Are Trading Lower By 26%; Here Are 20 Stocks Moving Premarket